Preparation method of L96 side chain compound
By simplifying the preparation process of L96 side chain compound III, the condensation reaction of dodecanediate monomethyl ester and N-hydroxysuccinimide is used, and the coupling protecting group reaction of acid binding agent and protective monomer is combined with the binding agent, and the binding reaction is carried out. Crystallization purification solves the problems of expensive raw materials, cumbersome steps and impurity A in the prior art, and realizes efficient and stable preparation of compound III, which is suitable for industrial production.
Patent Information
- Application Number
- CN202310554787.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-17
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2043-05-17
AI Technical Summary
In the existing field of GalNAc-siRNA targeted delivery, the raw materials are expensive during the preparation process of L96 side chain compound III, the synthesis steps are cumbersome, and column chromatography purification leads to the generation of impurity A, which affects the purity and yield of the product. The condensation reagent HBTU is costly and It is highly sensitized and not suitable for large-scale applications.
Condensation of monomethyl dodecanedic acid and N-hydroxysuccinimide to form an active ester intermediate, and then react with compound I, and conduct coupling protecting group reaction under the condition of acid binding agent in the aprotic solvent to obtain Compound III and product purity was increased by recrystallization purification.
The preparation of the cheap and easy-to-get Compound III is achieved, which shortens the reaction time, improves the yield and purity, avoids the generation of impurity A, is suitable for industrial production, and maintains chemical stability under long-term storage conditions.
Smart Images

Figure BDA0004232587410000011 
Figure BDA0004232587410000021 
Figure BDA0004232587410000022
Abstract
Description
Technical Field
[0001] The invention belongs to the field of pharmaceutical synthesis and relates to a method for preparing an L96 side chain compound, and specifically relates to a method for preparing a compound III. Background Art
[0002] GalNAc conjugation technology can be applied to both siRNA drugs and ASO drugs, and is the most effective small nucleic acid drug delivery system to date. GalNAc is a targeting ligand for the sialic acid glycoprotein receptor (ASGPR), which has a high affinity and rapid internalization ability with the ASGPR on the surface of hepatocytes. After GalNAc binds to ASGPR, it enters the cell through endocytosis to form endosomes, thereby bringing a sufficient number of nucleic acid drugs into the cell to achieve liver-targeted delivery of nucleic acid drugs. This type of siRNA conjugate has great application potential in the treatment of liver-related diseases involving gene overexpression.
[0003] Studies have shown that when the single dose of GalNAc-siRNA monoconjugate is 1μg / g, subcutaneous injection can achieve effective silencing of specific liver target genes, and the silencing efficiency far exceeds that of siRNA encapsulated in lipid nanoparticles. The chemically modified and optimized GalNAc-siRNA has better stability and interference efficiency. This type of siRNA conjugate has great application potential in the treatment of liver-related diseases involving abnormally high gene expression. The structure of the GalNAc-siRNA conjugate consists of three parts: a three-touch GalNAc target head, a linker arm, and a siRNA molecule. There are 4 nucleic acid drugs on the market worldwide that use the GalNAc conjugate delivery system, with indications covering hereditary metabolic diseases and cardiovascular system diseases, all of which use L96 as the delivery molecule. L96 includes a three-touch GalNAc target head (left half) and a linker arm (right half, side chain), and its structure is shown below:
[0004]
[0005] The L96 molecule is connected to the siRNA via the hydroxyl group of the side chain. US patent applications US32852808 and US201113326203 disclose a method for preparing L96. Both patent applications use the compound ((3R, 5S)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)pyrrolidin-3-ol) and the compound monomethyl dodecanedioate as raw materials, and condense to obtain the L96 side chain (Compound III). The specific synthesis route is as follows:
[0006]
[0007] At present, the above-mentioned synthetic route is mostly used in the field of GalNAc-siRNA targeted delivery, among which the synthetic steps of ((3R, 5S)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)pyrrolidin-3-ol) are long and expensive, resulting in a high cost of compound III. In addition, during the column chromatography purification process of compound III, silica gel easily leads to the removal of the DMT protecting group, resulting in impurity A, which is difficult to remove in the subsequent purification steps, and ultimately affects the purity of L96. The structure of impurity A is shown below:
[0008]
[0009] Chinese patent application 201780034659.0 discloses another preparation route of L96, as follows:
[0010]
[0011] (3R,5S)-5-(Hydroxymethyl)-5-methylpyrrolidin-3-ol hydrochloride (136) (7.9 g, 47.4 mmol), 12-methoxy-12-oxododecanoic acid (11.5 g, 47.4 mmol), HBTU (36 g, 76 mmol) and TEA (20 mL, 142.2 mmol) were stirred in DCM for 16 h at room temperature. The precipitate was removed by filtration and the organics were washed with 1M HCl (×2), saturated NaHCO (×2), H O and brine. After drying, the organics were concentrated in vacuo and purified by column chromatography (5% MeOH / DCM) to give methyl 12-((2S,4R)-4-hydroxy-2-(hydroxymethyl)-2-methylpyrrolidin-1-yl)-12-oxododecanoate (137) (3.1 g, 18.3%).
[0012] 12-((2S, 4R)-4-hydroxy-2-(hydroxymethyl)-2-methylpyrrolidin-1-yl)-12-oxo-dodecanoic acid methyl ester (137) (3.1 g, 9.0 mmol), DMT-Cl (2.8 g, 8.2 mmol) and TEA (1.1 mL, 8.2 mmol) were stirred in DCM for 16 hours at room temperature. The reaction was concentrated in vacuo and the residue was purified by column chromatography (5% MeOH / DCM, 0.1% TEA) to give 12-((2S, 4R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxy-2-methylpyrrolidin-1-yl)-12-oxo-dodecanoic acid methyl ester (138) (2.7 g, 45.5 mmol);
[0013] This solution has the following defects:
[0014] ① The product (138) was 2.7 g, which should be 4.09 mmol, with a yield of 47.2%, and the overall yield was low;
[0015] ② The condensation reagent used is HBTU, which is expensive and allergenic, and is not suitable for large-scale application;
[0016] ③ The two synthesis steps take 16 hours each, which is a long reaction time and is not suitable for industrial production;
[0017] ④ When column chromatography is used for purification, the product will have adsorption loss when passing through the column, affecting the yield; when passing through the column, the product may lose the DMTr protecting group to produce impurity A, affecting the purity of the product. Summary of the invention
[0018] The present invention provides a method for preparing a L96 side chain compound (Compound III) to overcome the deficiencies of the prior art. The starting raw materials of the method are cheap and readily available, the reaction conditions are mild, the reaction rate is fast, the product does not require column chromatography purification, the operation is simple, the yield is high, the product purity is high and the chemical properties are stable, and it is suitable for industrial production. The preparation route of the method is as follows:
[0019]
[0020] In one aspect, the present invention provides a method for preparing compound II, comprising the following steps:
[0021] A: reacting monomethyl dodecanedioate with N-hydroxysuccinimide and a condensing agent to generate an active ester intermediate;
[0022] B: Compound I and an acid-binding agent react with an active ester intermediate to obtain compound II.
[0023] In some embodiments, the molar ratio of the condensing agent to monomethyl dodecanedioate is 1.0 to 1.3:1.
[0024] In some embodiments, the molar ratio of the compound I to the active ester intermediate is 1.0-1.2:1.
[0025] In some embodiments, the molar ratio of the compound I to the acid binding agent is 1:1.5-3.0.
[0026] In some embodiments, the reaction temperature of step A is 0°C to 35°C, preferably 15°C to 20°C.
[0027] In some embodiments, the reaction time of step A is 2 to 3 hours.
[0028] In some embodiments, the reaction temperature of step B is 0°C to 35°C, preferably 15°C to 20°C.
[0029] In some embodiments, the reaction time of step B is 2 to 4 hours.
[0030] The structural formula of the active ester intermediate is shown below:
[0031]
[0032] In some embodiments, the condensing agent can be a carbodiimide reagent, preferably one or more of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI), dicyclohexylcarbodiimide (DCC) and N,N'-diisopropylcarbodiimide (DIC). More preferably, the condensing agent is EDCI.
[0033] In some embodiments, the acid binding agent is selected from one or more of pyridine, N,N-diisopropylethylamine (DIEA) and triethylamine.
[0034] Preferably, the acid binding agent is pyridine.
[0035] In some embodiments, the aprotic solvent is selected from one or more of dichloromethane, N,N-dimethylformamide and acetonitrile.
[0036] Preferably, the aprotic solvent is dichloromethane.
[0037] In another aspect, the present invention provides a method for preparing compound III, comprising the following steps:
[0038] C: In an aprotic solvent and in the presence of an acid-binding agent, the compound II is subjected to a coupling reaction with a protective monomer to obtain a crude compound III;
[0039]
[0040] In some embodiments, the mass-to-volume ratio of the compound II to the polar aprotic solvent is 1:5-15, the mass of the compound II is measured in g, and the volume of the polar aprotic solvent is measured in mL.
[0041] In some embodiments, the molar ratio of the compound II to the protective monomer is 1:1.0-1.1.
[0042] In some embodiments, the aprotic solvent is a polar aprotic solvent.
[0043] In some embodiments, the aprotic solvent is selected from one or more of dichloromethane, pyridine and N,N-dimethylformamide.
[0044] In some embodiments, the volume ratio of pyridine to N,N-dimethylformamide or dichloromethane is 1:8-12.
[0045] In some specific embodiments, the aprotic solvent is pyridine.
[0046] In some embodiments, the protecting monomer is DMT-Cl.
[0047] In some embodiments, the mass-to-volume ratio of the compound II to the aprotic solvent is 1:5-15, the mass of the compound II is measured in g, and the volume of the polar aprotic solvent is measured in mL.
[0048] In some embodiments, the molar ratio of compound II to DMT-Cl is 1:1.0-1.1.
[0049] In some embodiments, the reaction temperature of the coupling protecting group is 0°C to 30°C, preferably 10°C to 20°C.
[0050] In some embodiments, the method further comprises the following steps:
[0051] Add solvent, stir and wash, separate the liquids, add desiccant to the organic phase, dry, filter and concentrate.
[0052] Preferably, the solvent is selected from one or more of water, ethyl acetate, dichloromethane and butyl acetate.
[0053] In some embodiments, the method further comprises:
[0054] The crude compound III is purified by recrystallization, wherein the recrystallization comprises the following steps:
[0055] D: Mixing the crude compound III with the recrystallization solvent, and heating to a first temperature until the mixture is completely dissolved to obtain a feed solution;
[0056] E: Cooling the feed liquid to a precipitation temperature to precipitate solid;
[0057] F: Filter by suction and dry the filter cake in vacuum to obtain the purified compound III.
[0058] In some embodiments, the first temperature is 40°C to 55°C;
[0059] The precipitation temperature is -30°C to -20°C.
[0060] Preferably, said E comprises the following steps:
[0061] First, cool the feed liquid to 30°C-40°C, preferably 35°C, maintain for 2-4 hours, and then cool it down to the precipitation temperature.
[0062] More preferably, said E comprises the following steps:
[0063] First, the feed liquid is cooled to 30°C to 40°C, preferably 35°C, maintained for 2 to 4 hours, and then cooled to the precipitation temperature at a temperature reduction gradient of 0.1°C to 0.3°C / min, preferably 0.1°C / min.
[0064] Preferably, the recrystallization solvent is an ether reagent.
[0065] More preferably, the recrystallization solvent is selected from one or more of methyl tert-butyl ether, isopropyl ether and diethyl ether.
[0066] In some embodiments, the mass volume ratio of the crude compound III to the recrystallization solvent is 1:1-6, the mass of the crude compound III is measured in g, and the volume of the recrystallization solvent is measured in mL.
[0067] In some embodiments, the vacuum drying temperature is 25°C to 40°C, preferably 30°C.
[0068] The present invention has the following advantages and effects:
[0069] (1) The condensation reagent is EDCI, DCC or DIC, which is lower in cost and non-sensitizing;
[0070] (2) The reaction rate is fast, which shortens the reaction time and is suitable for industrial applications;
[0071] (3) The crude compound III is purified by recrystallization, with high yield, and the generation of impurity A is effectively avoided, thereby improving the purity of compound III;
[0072] (4) Compound III purified by the recrystallization method has excellent chemical stability. Its chemical properties remain stable under conditions of light, high temperature and high humidity for 10 days or more, and its purity does not decrease significantly. DETAILED DESCRIPTION
[0073] The present invention will be further described below in conjunction with specific embodiments, and the advantages and features of the present invention will become clearer as the description proceeds. However, these embodiments are exemplary only and do not constitute any limitation to the scope of the present invention. It should be understood by those skilled in the art that the details and forms of the technical solution of the present invention may be modified or replaced without departing from the spirit and scope of the present invention, but these modifications and replacements all fall within the scope of protection of the present invention.
[0074] The present invention provides a method for preparing a compound III. The method does not require column chromatography, can effectively remove impurity A generated during the synthesis process, and the chemical properties of the obtained compound III are stable.
[0075] Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as commonly used in the field to which the present invention belongs. For the purpose of interpreting this specification, the following definitions will apply, and where appropriate, terms used in the singular will also include the plural form, and vice versa.
[0076] As used herein, the articles "a," "an," and "an" include plural referents unless the context clearly dictates otherwise.
[0077] The term "purity" herein refers to the percentage of a substance having a certain chemical structure in a sample to the total mass of the sample. Preferably, the "purity" herein may refer to the purity of a compound measured by HPLC.
[0078] The term "acid binding agent" in the present invention refers to a reagent that can react chemically with an acidic substance to form salts or anhydrides. The acid binding agent reduces the acidity by binding the acidic components in the system.
[0079] The term "aprotic solvent" in the present invention refers to a solvent that has extremely weak proton self-transfer reaction or no proton self-transfer tendency.
[0080] Instruments used: Agilent 1260, Bruker NMR 400 MHz.
[0081] Example 1 Preparation of Compound II
[0082] Step A: Add 1.22g of monomethyl dodecanedioate, 0.61g of N-hydroxysuccinimide (NHS) and 15mL of dichloromethane to a flask, stir to dissolve, and control the temperature at 15°C to 20°C. Add 1.01g of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), stir to react for 2.5h, and monitor the reaction by TLC. Add 10mL of water, stir to wash, separate the liquids, and dry the organic phase with anhydrous sodium sulfate. Filter and remove the desiccant. Concentrate to obtain 1.70g of active ester intermediate with a yield of 99.7%.
[0083] Step B: Add 15mL of dichloromethane, 0.80g of (3R, 5S)-5-(hydroxymethyl)pyrrolidin-3-ol hydrochloride (Compound I) and 1.50g of N, N-diisopropylethylamine (DIEA) to a flask, and stir to dissolve. Control the temperature at 15°C-20°C, add 1.70g of active ester intermediate, and stir to react for 3h. TLC monitors the reaction to be complete. Wash with water, let stand, separate the liquids, and dry the organic phase with anhydrous sodium sulfate. Filter and remove the desiccant. Concentrate to obtain 1.62g of Compound II, with a yield of 94.7%. 1H NMR (400MHz, CDCl3): δ = 4.41 (m, 1H), 4.21 (m, 1H), 3.78 (d, 1H), 3.68 (m, 2H), 3.65 (s, 3H), 3.50(dd, 1H), 2.31(m, 4H), 2.07(m, 1H), 1.73(m, 1H), 1.61(m, 4H), 1.27(m, 12H).
[0084] Example 2 Preparation of Compound II
[0085] Step A: Add 1.22g of monomethyl dodecanedioate, 0.61g of N-hydroxysuccinimide (NHS) and 15mL of dichloromethane to a flask, stir to dissolve, and control the temperature at 15℃~20℃. Add 0.63g of diisopropylcarbodiimide (DIC), stir to react for 2.5h, and monitor the reaction by TLC. Add 10mL of water, stir to wash, separate the liquids, and dry the organic phase with anhydrous sodium sulfate. Filter and remove the desiccant. Concentrate to obtain 1.63g of active ester intermediate, with a yield of 95.3%.
[0086] Step B: Add 15mL N,N-dimethylformamide, 0.77g (3R, 5S)-5-(hydroxymethyl) pyrrolidin-3-ol hydrochloride (Compound I) and 1.50g N,N-diisopropylethylamine (DIEA) to a flask, and stir to dissolve. Control the temperature at 15℃~20℃, add 1.63g of active ester intermediate, and stir to react for 3h. TLC monitors the reaction to be complete. Add water and dichloromethane, stir and extract, let stand, separate the liquids, and add anhydrous sodium sulfate to dry the organic phase. Filter and remove the desiccant. Concentrate to obtain 1.6g of Compound II, with a yield of 97.6%.
[0087] Example 3 Preparation of Compound II
[0088] Step A: Add 1.22g of monomethyl dodecanedioate, 0.61g of N-hydroxysuccinimide (NHS) and 15mL of acetonitrile to a flask, stir to dissolve, and control the temperature at 15°C to 20°C. Add 1.03g of dicyclohexylcarbodiimide (DCC), stir to react for 2.5h, and monitor the reaction by TLC. Add 10mL of water, stir to wash, separate the liquids, and dry the organic phase with anhydrous sodium sulfate. Filter and remove the desiccant. Concentrate to obtain 1.71g of active ester intermediate, with a yield of 100%.
[0089] Step B: Add 15 mL of acetonitrile, 0.81 g of (3R, 5S)-5-(hydroxymethyl)pyrrolidin-3-ol hydrochloride (Compound I) and 1.50 g of N, N-diisopropylethylamine (DIEA) to a flask, and stir to dissolve. Control the temperature at 15°C to 20°C, add 1.71 g of active ester intermediate, stir to react for 3 hours, and monitor the reaction by TLC. Wash with water, let stand, and separate the liquids. Dry the organic phase with anhydrous sodium sulfate, filter, and remove the desiccant. Concentrate to obtain 1.65 g of Compound II, with a yield of 95.9%.
[0090] Example 4 Preparation of Compound III
[0091] Step C: Add 1.00 g of compound II and 1.5 mL of pyridine to 10 mL of dichloromethane, stir to dissolve, control the temperature at 10°C to 20°C, add 1.04 g of 4,4-dimethoxytriphenylmethane (DMT-Cl), stir to react for 1.5 h, and monitor the reaction completion by TLC.
[0092] Add 20 mL of water, stir and wash, separate the liquids, add anhydrous sodium sulfate to dry the organic phase, filter, remove the desiccant, and concentrate to obtain 2.07 g of crude compound III.
[0093] Step D: Add 10 mL of ether to the flask containing the crude compound III, heat to reflux, and stir until completely dissolved.
[0094] Step E: Cool the feed liquid to -30°C to precipitate solid.
[0095] Step F: Filter by suction, and dry the filter cake in vacuum at 30°C to obtain 1.72 g of white powdery solid with a yield of 91.5% and a HPLC purity of 98.38%. Impurity A was not detected.
[0096] Example 5 Preparation of Compound III
[0097] Step C: Add 1.00 g of compound II and 1.5 mL of pyridine to 10 mL of N,N-dimethylformamide, stir and dissolve. Control the temperature at 10°C to 20°C, add 1.04 g of 4,4-dimethoxytriphenylmethane chloride (DMT-Cl), stir and react for 1.5 h, and monitor the reaction completion by TLC.
[0098] Add 30 mL of ethyl acetate and 30 mL of water, stir and wash, separate the liquids, add anhydrous sodium sulfate to dry the organic phase, filter, remove the desiccant, and concentrate to obtain 2.11 g of crude compound III.
[0099] Step D: Add 10 mL of isopropyl ether to the flask containing the crude compound III, heat to 50°C, and stir until completely dissolved.
[0100] Step E: Cool the feed liquid to -30°C to precipitate solid.
[0101] Step F: Filter by suction, and dry the filter cake in vacuum at 30°C to obtain 1.64 g of white powdery solid with a yield of 87.2% and a HPLC purity of 97.84%. Impurity A was not detected.
[0102] Example 6 Preparation of Compound III
[0103] Step C: Add 1.00 g of compound II to 10 mL of pyridine and stir to dissolve. Control the temperature at 10°C to 20°C, add 1.40 g of 4,4-dimethoxytriphenylmethane chloride (DMT-Cl), and stir to react for 1.5 hours. TLC monitors the reaction to be complete.
[0104] Add 30 mL of ethyl acetate and 30 mL of water, stir and wash, separate the liquids, add anhydrous sodium sulfate to dry the organic phase, filter, remove the desiccant, and concentrate to obtain 1.88 g of crude compound III.
[0105] Step D: Add 10 mL of methyl tert-butyl ether to the flask containing the crude compound III, heat to 45°C, and stir until completely dissolved.
[0106] Step E: Cool down to 35°C and keep at 35°C for 2-4 hours until solid precipitates. Then, cool the feed liquid to -30°C.
[0107] Step F: Filter by suction, and dry the filter cake in vacuum at 30°C to obtain 1.69 g of white powdery solid with a yield of 89.9% and a HPLC purity of 99.12%. Impurity A was not detected.
[0108] Example 7 Preparation of Compound III
[0109] Step C: Add 1.00 g of compound II to 10 mL of pyridine and stir to dissolve. Control the temperature at 10°C-20°C, add 1.40 g of 4,4-dimethoxytriphenylmethane chloride (DMT-Cl), and stir to react for 1.5 hours. TLC monitors the reaction to be complete.
[0110] Add 30 mL of ethyl acetate and 30 mL of water, stir and wash, separate the liquids, add anhydrous sodium sulfate to dry the organic phase, filter, remove the desiccant, and concentrate to obtain 1.92 g of crude compound III.
[0111] Step D: Add 10 mL of methyl tert-butyl ether to the flask containing the crude compound III, heat to 45°C, and stir until completely dissolved.
[0112] Step E: Cool down to 35°C and keep at 35°C for 2-4 hours until solid precipitates. Then, cool the feed solution to -20°C at a temperature drop gradient of 0.3°C / min.
[0113] Step F: Filter by suction, and dry the filter cake in vacuum at 30°C to obtain 1.74 g of white powdery solid with a yield of 92.5% and a HPLC purity of 99.30%. Impurity A was not detected.
[0114] Example 8 Preparation of Compound III
[0115] Step C: Add 1.00 g of compound II to 10 mL of pyridine and stir to dissolve. Control the temperature at 10°C to 20°C, add 1.40 g of 4,4-dimethoxytriphenylmethane chloride (DMT-Cl), and stir to react for 1.5 hours. TLC monitors the reaction to be complete.
[0116] Add 30 mL of ethyl acetate and 30 mL of water, stir and wash, separate the liquids, add anhydrous sodium sulfate to dry the organic phase, filter, remove the desiccant, and concentrate to obtain 1.85 g of crude compound III.
[0117] Step D: Add 10 mL of methyl tert-butyl ether to the flask containing the crude compound III, heat to 45°C, and stir until completely dissolved.
[0118] Step E: Cool down to 35°C and keep at 35°C for 2-4 hours until solid precipitates. Then, cool the feed solution to -20°C at a temperature drop gradient of 0.2°C / min.
[0119] Step F: Filter by suction, and dry the filter cake in vacuum at 30°C to obtain 1.64 g of white powdery solid with a yield of 87.2% and a HPLC purity of 99.36%. Impurity A was not detected.
[0120] Example 9 Preparation of Compound III
[0121] Step C: Add 1.00 g of compound II to 10 mL of pyridine and stir to dissolve. Control the temperature at 10°C to 20°C, add 1.40 g of 4,4-dimethoxytriphenylmethane chloride (DMT-Cl), and stir to react for 1.5 hours. TLC monitors the reaction to be complete.
[0122] Add 30 mL of ethyl acetate and 30 mL of water, stir and wash, separate the liquids, add anhydrous sodium sulfate to dry the organic phase, filter, remove the desiccant, and concentrate to obtain 1.97 g of crude compound III.
[0123] Step D: Add 10 mL of methyl tert-butyl ether to the flask containing the crude compound III, heat to 45°C, and stir until completely dissolved.
[0124] Step E: Cool down to 35°C and keep at 35°C for 2-4 hours until solid precipitates. Then, cool the feed solution to -20°C at a temperature drop gradient of 0.1°C / min.
[0125] Step F: Filter by suction, and dry the filter cake in vacuum at 30°C to obtain 1.69 g of white powdery solid with a yield of 89.9% and a HPLC purity of 99.62%. Impurity A was not detected.
[0126] Comparative Example 1 Preparation of Compound III (US20120136042A1)
[0127] This example uses the preparation method of compound III disclosed in US20120136042A1 as a comparison.
[0128] 3.00 g of (3R, 5S)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)pyrrolidin-3-ol and 1.75 g of monomethyl dodecanedioate were added to 50 mL of N, N-dimethylformamide. 3.25 g of O-benzotriazole-tetramethyluronium hexafluorophosphate and 3.7 mL of N, N-diisopropylethylamine were added and stirred overnight. The reaction mixture was poured into an ice-water mixture and extracted with dichloromethane. The organic phase was washed with sodium bicarbonate aqueous solution, water and brine, respectively, and dried over anhydrous sodium sulfate. Concentration and purification on a silica gel column (eluted with 50% ethyl acetate / n-hexane and 5% methanol / dichloromethane) gave 3.97 g of a white solid with a yield of 88.2%, HPLC purity of 96.78%, and an impurity A content of 1.33%.
[0129] Comparative Example 2 Preparation of Compound III (CN109312342A)
[0130] This example uses the preparation method of compound III disclosed in CN109312342A as a comparison.
[0131] (3R, 5S)-5-(Hydroxymethyl)-5-methylpyrrolidin-3-ol hydrochloride (136) (7.9 g, 47.4 mmol), 12-methoxy-12-oxododecanoic acid (11.5 g, 47.4 mmol), HBTU (36 g, 76 mmol) and TEA (triethylamine) (20 mL, 142.2 mmol) were stirred in DCM for 16 hours at room temperature. The precipitate was removed by filtration and the organics were washed with 1M HCl (×2), saturated NaHCO (×2), H O and brine. After drying, the organics were concentrated in vacuo and purified by column chromatography (5% MeOH / DCM) to give methyl 12-((2S, 4R)-4-hydroxy-2-(hydroxymethyl)-2-methylpyrrolidin-1-yl)-12-oxododecanoate (137) (3.1 g, 18.3%).
[0132] Methyl 12-((2S,4R)-4-hydroxy-2-(hydroxymethyl)-2-methylpyrrolidin-1-yl)-12-oxododecanoate (137) (3.1 g, 9.0 mmol), DMT-Cl (4,4'-dimethoxytriphenylmethane)
[0133] (2.8 g, 8.2 mmol) and TEA (1.1 mL, 8.2 mmol) were stirred in DCM (reasonably assumed to be DCM) for 16 hours. The reaction was concentrated in vacuo and the residue was purified by column chromatography (5% MeOH / DCM, 0.1% TEA) to give 12-((2S,4R)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxy-2-methylpyrrolidin-1-yl)-12-oxododecanoic acid methyl ester (138) (2.7 g, 45.5 mmol).
[0134] The data in the above scheme disclosed in CN109312342A were calculated incorrectly. The product (138) was obtained at 2.7 g, which should be 4.09 mmol, with a yield of 47.2%.
[0135] Table 1 summarizes the yield, purity and other characterization data of Compound III in Examples 4-9 and Comparative Examples 1-2 under different purification conditions for comparison:
[0136] Table 1 Comparison of purification conditions and results of compound III
[0137]
[0138]
[0139] Stability test
[0140] This example investigates the chemical stability of compound III prepared by different methods.
[0141] The compounds III prepared in Example 4, Example 5, Example 9 and Comparative Example 1 were weighed respectively, and stability tests were performed according to the guidance method for stability investigation in Part IV of the Chinese Pharmacopoeia. The purity was tested by HPLC. The specific test results are shown in Table 2.
[0142] Table 2 Stability test results of different products under different conditions
[0143]
[0144]
[0145] As can be seen from Table 2, the purity of the compound III prepared by the present invention did not change significantly under the conditions of light, high temperature and high humidity, and no impurity A was detected. However, the purity of the product of Comparative Example 1 using the method disclosed in US20120136042A1 was greatly reduced under the same experimental conditions, and the content of impurity A and total impurities increased significantly, that is, deterioration occurred, which shows that the compound III prepared by the present invention has good chemical stability.
[0146] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.
Claims
1. A method for preparing compound II, characterized in that: The method comprises the following steps: A: In an aprotic solvent, monomethyl dodecanedioate reacts with N-hydroxysuccinimide and a condensation agent to form an active ester intermediate; B: reacting compound I and an acid-binding agent with an active ester intermediate to obtain compound II; 2. The method according to claim 1, characterized in that The condensing agent is carbodiimide.
3. The method according to claim 2, characterized in that The condensing agent is selected from one or more of EDCI, DCC and DIC.
4. The method according to claim 1, characterized in that The acid binding agent is selected from one or more of pyridine, N,N-diisopropylethylamine and triethylamine.
5. The method according to claim 1, characterized in that The aprotic solvent is selected from one or more of dichloromethane, N,N-dimethylformamide and acetonitrile.
6. A method for preparing compound III, characterized in that: The method comprises the following steps: C: In an aprotic solvent, in the presence of an acid-binding agent, coupling the compound II prepared by the method according to any one of claims 1 to 5 with a protective monomer to obtain a crude compound III; 7. The method according to claim 6, characterized in that The aprotic solvent is a polar aprotic solvent.
8. The method according to claim 7, characterized in that The aprotic solvent is selected from one or more of dichloromethane, pyridine and N,N-dimethylformamide.
9. The method according to claim 6, characterized in that The protecting monomer is DMT-Cl.
10. The method according to claim 6, characterized in that The method further comprises: The crude compound III is purified by recrystallization, wherein the recrystallization comprises the following steps: D: Mixing the crude compound III with the recrystallization solvent, and heating to a first temperature until the mixture is completely dissolved to obtain a feed solution; E: Cooling the feed liquid to a precipitation temperature to precipitate solid; F: Filtration and drying to obtain the purified compound III.
11. The method according to claim 10, characterized in that The E comprises the following steps: First, cool the feed liquid to 30℃~40℃, maintain for 2~4h, and then cool it down to the precipitation temperature.
12. The method according to claim 10, characterized in that The E comprises the following steps: First, cool the feed liquid to 30°C-40°C, maintain for 2-4 hours, and then cool to the precipitation temperature at a temperature drop gradient of 0.1-0.3°C / min.
13. The method according to claim 10, characterized in that The recrystallization solvent is ether.
14. The method according to claim 13, characterized in that The recrystallization solvent is selected from one or more of methyl tert-butyl ether, isopropyl ether and diethyl ether.
15. The method according to claim 10, characterized in that The first temperature is 40°C to 55°C; the precipitation temperature is -30°C to -20°C.
Citation Information
Patent Citations
Targeted nucleic acid conjugate compositions
CN109312342A
Therapeutic methods
CN113365662A
Carbohydrate conjugates as delivery agents for oligonucleotides
US20120136042A1
Glucose responsive insulin comprising a tri-valent sugar cluster for treatment of diabetes
US20200087375A1
Carbohydrate conjugates as delivery agents for oligonucleotides
WO2009073809A2
